LY 3549492
Alternative Names: LY-3549492Latest Information Update: 28 Jun 2025
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Combination therapy, Treatment-experienced) in Germany (PO)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Treatment-experienced) in Germany (PO)
- 22 Jun 2025 Eli Lilly and Company plans to initiate a phase II trial for Obesity and Type 2 diabetes mellitus in the US and Argentina (PO) (NCT07030868)